SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV, a foreign private issuer headquartered in Mechelen, Belgium. The filing covers the month of January 2022 and was submitted on January 10, 2022. The document serves to incorporate by reference a press release dated January 6, 2022 (Exhibit 99.1). Note: While the request metadata mentions "Lakefront Biotherapeutics NV," the filing text explicitly identifies the registrant as Galapagos NV.
Financial Metrics
The filing text does not provide specific financial data. This report is a procedural filing to distribute a press release and does not contain revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The filing does not detail material changes in financial position or operations within the text provided. It references an attached press release (Exhibit 99.1) for the specific material event or announcement made on January 6, 2022, but the content of that press release is not included in the source text.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided text. The filing strictly incorporates the referenced press release by reference into the company's Registration Statements on Forms F-3 and S-8.
Key Facts for Investor Verification
- Verify the content of the press release dated January 6, 2022 (Exhibit 99.1), as the specific material event is not detailed in this summary text.
- Confirm the registrant identity is Galapagos NV, not Lakefront Biotherapeutics NV.
- Note that this filing incorporates information into multiple active Registration Statements (Forms F-3 and S-8).
- Check for subsequent filings if the press release contained forward-looking statements or clinical trial updates requiring further disclosure.